Figure 1

Distribution of MDSCs in patients with CRC. (A) Gating strategy for the assessment of the MDSC population using flow cytometry. HLA-DR⁻ cells were gated from live PBMCs, and CD33⁺CD11b⁺ cells were further gated as MDSCs. Representative density plots from two CRC patients and healthy donors are shown. (B) The dot plots represent CD33⁺CD11b⁺ MDSC gating from the HLA-DR⁻CD45⁺ cell fraction from the tumorous and paraneoplastic tissues of one CRC patient. (C) Statistical analysis of the percentage of MDSCs among the PBMCs from CRC patients (n = 42) and healthy donors (n = 32). (D) The proportion of MDSCs was significantly increased in tumorous tissues compared with paraneoplastic tissues and PBMCs from CRC patients (n = 19). Error bars represent SEM.